Results from the SECURE (Surveillance Epidemiology of Coronavirus Under Research Exclusion) IBD database reported that IBD patients under treatment with anti-TNF-α therapy who were diagnosed with COVID-19 showed equal or even better clinical outcomes than patients without prior treatment with the TNF-α -blocking drugs [52]. This evidence concerns the gene TNF and COVID-19.